Trial Profile
Phase 1 trial of CAT-4001 in patients with Friedreich's ataxia and Amyotrophic Lateral Sclerosis (ALS)
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2022
Price :
$35
*
At a glance
- Drugs Docosahexaenoic acid-citraconic acid conjugate (Primary)
- Indications Amyotrophic lateral sclerosis; Friedreich's ataxia
- Focus Adverse reactions
- 08 Mar 2016 New trial record
- 02 Mar 2016 According to Catabasis media release, company is planning to initiate this trial in 2017.